Technische Universität München, Institut für Pathologie, Trogerstrasse 18, 81675 München, Germany.
Eur J Cancer. 2010 Jan;46(1):47-55. doi: 10.1016/j.ejca.2009.10.016.
In most hospitals word-wide, histopathological cancer diagnosis is currently based on formalin-fixed and paraffin-embedded (FFPE) tissues. In the last few years new approaches and developments in patient-tailored cancer therapy have raised the need to select more precisely those patients, who will respond to personalised treatments. The most efficient way for optimal therapy and patient selection is probably to provide a tumour-specific protein network portrait prior to treatment. The discovery and characterisation of deregulated signalling molecules (e.g. human epidermal growth factor receptor 2, mitogen-activated protein kinases) are very promising candidates for the identification of new suitable therapy targets and for the selection of those patients who will receive the greatest benefit from individualised treatments. The reverse phase protein array (RPPA) is a promising new technology that allows quick, precise and simultaneous analysis of many components of a network. Importantly it requires only limited amounts of routine clinical material (e.g. FFPE biopsies) and can be used for absolute protein measurements. We and other research groups have described successful protein extraction from routine FFPE tissues. In this manuscript we show how these recent developments might facilitate the implementation of RPPA in clinical trials and routine settings.
在全球大多数医院，组织病理学癌症诊断目前基于福尔马林固定和石蜡包埋（FFPE）组织。在过去几年中，针对患者的癌症治疗新方法和新进展提出了更精确选择那些将对个性化治疗有反应的患者的需求。对于最佳治疗和患者选择来说，最有效的方法可能是在治疗前提供肿瘤特异性蛋白质网络图谱。失调信号分子（例如人表皮生长因子受体 2、丝裂原活化蛋白激酶）的发现和特征是识别新的合适治疗靶点和选择那些将从个体化治疗中获益最大的患者的非常有前途的候选者。反向蛋白质阵列（RPPA）是一种很有前途的新技术，可快速、精确和同时分析网络的许多成分。重要的是，它只需要有限数量的常规临床材料（例如 FFPE 活检），并且可以用于绝对蛋白质测量。我们和其他研究小组已经描述了从常规 FFPE 组织中成功提取蛋白质。在本文中，我们展示了这些最新进展如何促进 RPPA 在临床试验和常规环境中的实施。
